The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Transgenic plants in the biopharmaceutical market
Abstract
Many of our 'small-molecule-drugs' are natural products from plants, or are synthetic compounds based on molecules found naturally in plants. However, the vast majority of the protein therapeutics (or biopharmaceuticals) we use are from animal or human sources, and are produced commercially in microbial or mammalian bioreactor systems. Over the last few years, it has become clear that plants have great potential for the production of human proteins and other protein-based therapeutic entities. Plants offer the prospect of inexpensive biopharmaceutical production without sacrificing product quality or safety, and following the success of several plant-derived technical proteins, the first therapeutic products are now approaching the market. In this review, the different plant-based production systems are discussed and the merits of transgenic plants are evaluated compared with other platforms. A detailed discussion is provided of the development issues that remain to be addressed before plants become an acceptable mainstream production technology. The many different proteins that have already been produced using plants are described, and a sketch of the current market and the activities of the key players is provided. Despite the currently unclear regulatory framework and general industry inertia, the benefits of plant-derived pharmaceuticals are now bringing the prospect of inexpensive veterinary and human medicines closer than ever before.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Secretory and extracellular production of recombinant proteins using Escherichia coli
Choi, J. H., & Lee, S. Y. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-004-1559-9 · Cited by 614
Cited by
Ma, J. K. ‐., Barros, E., Bock, R., Christou, P., Dale, P. J., Dix, P. J., Fischer, R., Irwin, J., Mahoney, R., Pezzotti, M., et al. (2005) · EMBO reports · doi:10.1038/sj.embor.7400470 · Cited by 321
Self-citationMa, J. K., Drossard, J., Lewis, D., Altmann, F., Boyle, J., Christou, P., Cole, T., Dale, P., van Dolleweerd, C. J., Isitt, V., et al. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12416 · Cited by 261
Self-citationCritical Analysis of the Commercial Potential of Plants for the Production of Recombinant Proteins
Schillberg, S., Raven, N., Spiegel, H., Rasche, S., & Buntru, M. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.00720 · Cited by 261
Self-citationGenetically modified plants and human health
Key, S., Ma, J. K.-C., & Drake, P. M. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.070372 · Cited by 197
Karg, S. R., Frey, A. D., Ferrara, C., Streich, D. K., Umaña, P., & Kallio, P. T. (2009) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2008.10.005 · Cited by 19
Metadata
- Authors
- Twyman, R. M., Schillberg, S., & Fischer, R.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2005-02
- Volume
- 10
- Issue
- 1
- Pages
- 185-218
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2104061791
- Cited by
- 206
- References
- 2
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transgenic plants in the biopharmaceutical market. https://app.cochat.ai/papers/10.1517/14728214.10.1.185
- The paper
- Twyman, R. M., Schillberg, S., & Fischer, R. (2005). Transgenic plants in the biopharmaceutical market. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.10.1.185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.